Yamamoto S, et al. - Researchers sought to determine the superiority of 0.9 mg/day liraglutide plus basal insulin (Lira-basal) over basal-bolus insulin therapy (BBIT) for the treatment of type 2 diabetes (T2DM) without severe insulin deficiency as assessed by glucagon stimulation. The exclusion criteria involved subjects with fasting C-peptide immunoreactivity (CPR) < 1.0 ng/mL and CPR increase < 1.0 ng/mL at 6 min post-glucagon. The positive aspects of Lira-basal therapy were found to be as follows: A reduction in HbA1c, considerably reduced pre-breakfast and pre-lunch 7-point self-monitored blood glucose (SMBG), improvement in the Diabetes Treatment Satisfaction Questionnaire status (DTSQ) scores. Therefore, Lira-basal therapy was inferred to be superior to BBIT for T2DM without severe insulin deficiency.